img

Global Vaccine for Non-infectious Meningitis Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Vaccine for Non-infectious Meningitis Market Insights, Forecast to 2034

Meningococcal conjugate vaccine is used to prevent infection caused by meningococcal bacteria.
Global Vaccine for Non-infectious Meningitis market is expected to reach to US$ 1 million in 2024, with a positive growth of %, compared with US$ 1 million in 2022. Backed with the increasing demand from downstream industries, Vaccine for Non-infectious Meningitis industry is evaluated to reach US$ 2 million in 2029. The CAGR will be 12.0% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Vaccine for Non-infectious Meningitis market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Vaccine for Non-infectious Meningitis market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Serum Institute
Sanofi SA
Pfizer
Nuron Biotech
JN-International Medical
Segment by Type
Polysaccharide Vaccines
Conjugate Vaccines
Combination Vaccines
Men B Vaccines

Segment by Application


Meningitis
Septicemia
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Vaccine for Non-infectious Meningitis plant distribution, commercial date of Vaccine for Non-infectious Meningitis, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Vaccine for Non-infectious Meningitis introduction, etc. Vaccine for Non-infectious Meningitis Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Vaccine for Non-infectious Meningitis
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Vaccine for Non-infectious Meningitis Product Introduction
1.2 Market by Type
1.2.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Polysaccharide Vaccines
1.2.3 Conjugate Vaccines
1.2.4 Combination Vaccines
1.2.5 Men B Vaccines
1.3 Market by Application
1.3.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Meningitis
1.3.3 Septicemia
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Vaccine for Non-infectious Meningitis Sales Estimates and Forecasts 2018-2029
2.2 Global Vaccine for Non-infectious Meningitis Revenue by Region
2.2.1 Global Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Vaccine for Non-infectious Meningitis Revenue by Region (2018-2024)
2.2.3 Global Vaccine for Non-infectious Meningitis Revenue by Region (2024-2029)
2.2.4 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region (2018-2029)
2.3 Global Vaccine for Non-infectious Meningitis Sales Estimates and Forecasts 2018-2029
2.4 Global Vaccine for Non-infectious Meningitis Sales by Region
2.4.1 Global Vaccine for Non-infectious Meningitis Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Vaccine for Non-infectious Meningitis Sales by Region (2018-2024)
2.4.3 Global Vaccine for Non-infectious Meningitis Sales by Region (2024-2029)
2.4.4 Global Vaccine for Non-infectious Meningitis Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Vaccine for Non-infectious Meningitis Sales by Manufacturers
3.1.1 Global Vaccine for Non-infectious Meningitis Sales by Manufacturers (2018-2024)
3.1.2 Global Vaccine for Non-infectious Meningitis Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vaccine for Non-infectious Meningitis in 2022
3.2 Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers
3.2.1 Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers (2018-2024)
3.2.2 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Vaccine for Non-infectious Meningitis Revenue in 2022
3.3 Global Key Players of Vaccine for Non-infectious Meningitis, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Vaccine for Non-infectious Meningitis Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vaccine for Non-infectious Meningitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Product Offered and Application
3.8 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Vaccine for Non-infectious Meningitis Sales by Type
4.1.1 Global Vaccine for Non-infectious Meningitis Historical Sales by Type (2018-2024)
4.1.2 Global Vaccine for Non-infectious Meningitis Forecasted Sales by Type (2024-2029)
4.1.3 Global Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
4.2 Global Vaccine for Non-infectious Meningitis Revenue by Type
4.2.1 Global Vaccine for Non-infectious Meningitis Historical Revenue by Type (2018-2024)
4.2.2 Global Vaccine for Non-infectious Meningitis Forecasted Revenue by Type (2024-2029)
4.2.3 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
4.3 Global Vaccine for Non-infectious Meningitis Price by Type
4.3.1 Global Vaccine for Non-infectious Meningitis Price by Type (2018-2024)
4.3.2 Global Vaccine for Non-infectious Meningitis Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Vaccine for Non-infectious Meningitis Sales by Application
5.1.1 Global Vaccine for Non-infectious Meningitis Historical Sales by Application (2018-2024)
5.1.2 Global Vaccine for Non-infectious Meningitis Forecasted Sales by Application (2024-2029)
5.1.3 Global Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
5.2 Global Vaccine for Non-infectious Meningitis Revenue by Application
5.2.1 Global Vaccine for Non-infectious Meningitis Historical Revenue by Application (2018-2024)
5.2.2 Global Vaccine for Non-infectious Meningitis Forecasted Revenue by Application (2024-2029)
5.2.3 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
5.3 Global Vaccine for Non-infectious Meningitis Price by Application
5.3.1 Global Vaccine for Non-infectious Meningitis Price by Application (2018-2024)
5.3.2 Global Vaccine for Non-infectious Meningitis Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Vaccine for Non-infectious Meningitis Market Size by Type
6.1.1 US & Canada Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
6.1.2 US & Canada Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
6.2 US & Canada Vaccine for Non-infectious Meningitis Market Size by Application
6.2.1 US & Canada Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
6.2.2 US & Canada Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
6.3 US & Canada Vaccine for Non-infectious Meningitis Market Size by Country
6.3.1 US & Canada Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Vaccine for Non-infectious Meningitis Sales by Country (2018-2029)
6.3.3 US & Canada Vaccine for Non-infectious Meningitis Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Vaccine for Non-infectious Meningitis Market Size by Type
7.1.1 Europe Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
7.1.2 Europe Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
7.2 Europe Vaccine for Non-infectious Meningitis Market Size by Application
7.2.1 Europe Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
7.2.2 Europe Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
7.3 Europe Vaccine for Non-infectious Meningitis Market Size by Country
7.3.1 Europe Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Vaccine for Non-infectious Meningitis Sales by Country (2018-2029)
7.3.3 Europe Vaccine for Non-infectious Meningitis Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Vaccine for Non-infectious Meningitis Market Size
8.1.1 China Vaccine for Non-infectious Meningitis Sales (2018-2029)
8.1.2 China Vaccine for Non-infectious Meningitis Revenue (2018-2029)
8.2 China Vaccine for Non-infectious Meningitis Market Size by Application
8.2.1 China Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
8.2.2 China Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Vaccine for Non-infectious Meningitis Market Size by Type
9.1.1 Asia Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
9.1.2 Asia Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
9.2 Asia Vaccine for Non-infectious Meningitis Market Size by Application
9.2.1 Asia Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
9.2.2 Asia Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
9.3 Asia Vaccine for Non-infectious Meningitis Sales by Region
9.3.1 Asia Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Vaccine for Non-infectious Meningitis Revenue by Region (2018-2029)
9.3.3 Asia Vaccine for Non-infectious Meningitis Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Market Size by Type
10.1.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Market Size by Application
10.2.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Country
10.3.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Serum Institute
11.1.1 Serum Institute Company Information
11.1.2 Serum Institute Overview
11.1.3 Serum Institute Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Serum Institute Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Serum Institute Recent Developments
11.2 Sanofi SA
11.2.1 Sanofi SA Company Information
11.2.2 Sanofi SA Overview
11.2.3 Sanofi SA Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Sanofi SA Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi SA Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Pfizer Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Nuron Biotech
11.4.1 Nuron Biotech Company Information
11.4.2 Nuron Biotech Overview
11.4.3 Nuron Biotech Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Nuron Biotech Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Nuron Biotech Recent Developments
11.5 JN-International Medical
11.5.1 JN-International Medical Company Information
11.5.2 JN-International Medical Overview
11.5.3 JN-International Medical Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 JN-International Medical Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 JN-International Medical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Vaccine for Non-infectious Meningitis Industry Chain Analysis
12.2 Vaccine for Non-infectious Meningitis Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccine for Non-infectious Meningitis Production Mode & Process
12.4 Vaccine for Non-infectious Meningitis Sales and Marketing
12.4.1 Vaccine for Non-infectious Meningitis Sales Channels
12.4.2 Vaccine for Non-infectious Meningitis Distributors
12.5 Vaccine for Non-infectious Meningitis Customers
13 Market Dynamics
13.1 Vaccine for Non-infectious Meningitis Industry Trends
13.2 Vaccine for Non-infectious Meningitis Market Drivers
13.3 Vaccine for Non-infectious Meningitis Market Challenges
13.4 Vaccine for Non-infectious Meningitis Market Restraints
14 Key Findings in The Global Vaccine for Non-infectious Meningitis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Polysaccharide Vaccines
Table 3. Major Manufacturers of Conjugate Vaccines
Table 4. Major Manufacturers of Combination Vaccines
Table 5. Major Manufacturers of Men B Vaccines
Table 6. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Vaccine for Non-infectious Meningitis Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Vaccine for Non-infectious Meningitis Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Vaccine for Non-infectious Meningitis Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region (2018-2024)
Table 11. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region (2024-2029)
Table 12. Global Vaccine for Non-infectious Meningitis Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Vaccine for Non-infectious Meningitis Sales by Region (2018-2024) & (K Units)
Table 14. Global Vaccine for Non-infectious Meningitis Sales by Region (2024-2029) & (K Units)
Table 15. Global Vaccine for Non-infectious Meningitis Sales Market Share by Region (2018-2024)
Table 16. Global Vaccine for Non-infectious Meningitis Sales Market Share by Region (2024-2029)
Table 17. Global Vaccine for Non-infectious Meningitis Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Vaccine for Non-infectious Meningitis Sales Share by Manufacturers (2018-2024)
Table 19. Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Vaccine for Non-infectious Meningitis Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Vaccine for Non-infectious Meningitis, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Vaccine for Non-infectious Meningitis Price by Manufacturers 2018-2024 (USD/Unit)
Table 23. Global Vaccine for Non-infectious Meningitis Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Vaccine for Non-infectious Meningitis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine for Non-infectious Meningitis as of 2022)
Table 25. Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Product Offered and Application
Table 27. Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Vaccine for Non-infectious Meningitis Sales by Type (2018-2024) & (K Units)
Table 30. Global Vaccine for Non-infectious Meningitis Sales by Type (2024-2029) & (K Units)
Table 31. Global Vaccine for Non-infectious Meningitis Sales Share by Type (2018-2024)
Table 32. Global Vaccine for Non-infectious Meningitis Sales Share by Type (2024-2029)
Table 33. Global Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Vaccine for Non-infectious Meningitis Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Vaccine for Non-infectious Meningitis Revenue Share by Type (2018-2024)
Table 36. Global Vaccine for Non-infectious Meningitis Revenue Share by Type (2024-2029)
Table 37. Vaccine for Non-infectious Meningitis Price by Type (2018-2024) & (USD/Unit)
Table 38. Global Vaccine for Non-infectious Meningitis Price Forecast by Type (2024-2029) & (USD/Unit)
Table 39. Global Vaccine for Non-infectious Meningitis Sales by Application (2018-2024) & (K Units)
Table 40. Global Vaccine for Non-infectious Meningitis Sales by Application (2024-2029) & (K Units)
Table 41. Global Vaccine for Non-infectious Meningitis Sales Share by Application (2018-2024)
Table 42. Global Vaccine for Non-infectious Meningitis Sales Share by Application (2024-2029)
Table 43. Global Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Vaccine for Non-infectious Meningitis Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Vaccine for Non-infectious Meningitis Revenue Share by Application (2018-2024)
Table 46. Global Vaccine for Non-infectious Meningitis Revenue Share by Application (2024-2029)
Table 47. Vaccine for Non-infectious Meningitis Price by Application (2018-2024) & (USD/Unit)
Table 48. Global Vaccine for Non-infectious Meningitis Price Forecast by Application (2024-2029) & (USD/Unit)
Table 49. US & Canada Vaccine for Non-infectious Meningitis Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Vaccine for Non-infectious Meningitis Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Vaccine for Non-infectious Meningitis Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Vaccine for Non-infectious Meningitis Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Vaccine for Non-infectious Meningitis Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Vaccine for Non-infectious Meningitis Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Vaccine for Non-infectious Meningitis Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Vaccine for Non-infectious Meningitis Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Vaccine for Non-infectious Meningitis Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Vaccine for Non-infectious Meningitis Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Vaccine for Non-infectious Meningitis Sales by Country (2024-2029) & (K Units)
Table 62. Europe Vaccine for Non-infectious Meningitis Sales by Type (2018-2024) & (K Units)
Table 63. Europe Vaccine for Non-infectious Meningitis Sales by Type (2024-2029) & (K Units)
Table 64. Europe Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Vaccine for Non-infectious Meningitis Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Vaccine for Non-infectious Meningitis Sales by Application (2018-2024) & (K Units)
Table 67. Europe Vaccine for Non-infectious Meningitis Sales by Application (2024-2029) & (K Units)
Table 68. Europe Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Vaccine for Non-infectious Meningitis Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Vaccine for Non-infectious Meningitis Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Vaccine for Non-infectious Meningitis Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Vaccine for Non-infectious Meningitis Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Vaccine for Non-infectious Meningitis Sales by Country (2018-2024) & (K Units)
Table 74. Europe Vaccine for Non-infectious Meningitis Sales by Country (2024-2029) & (K Units)
Table 75. China Vaccine for Non-infectious Meningitis Sales by Type (2018-2024) & (K Units)
Table 76. China Vaccine for Non-infectious Meningitis Sales by Type (2024-2029) & (K Units)
Table 77. China Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Vaccine for Non-infectious Meningitis Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Vaccine for Non-infectious Meningitis Sales by Application (2018-2024) & (K Units)
Table 80. China Vaccine for Non-infectious Meningitis Sales by Application (2024-2029) & (K Units)
Table 81. China Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Vaccine for Non-infectious Meningitis Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Vaccine for Non-infectious Meningitis Sales by Type (2018-2024) & (K Units)
Table 84. Asia Vaccine for Non-infectious Meningitis Sales by Type (2024-2029) & (K Units)
Table 85. Asia Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Vaccine for Non-infectious Meningitis Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Vaccine for Non-infectious Meningitis Sales by Application (2018-2024) & (K Units)
Table 88. Asia Vaccine for Non-infectious Meningitis Sales by Application (2024-2029) & (K Units)
Table 89. Asia Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Vaccine for Non-infectious Meningitis Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Vaccine for Non-infectious Meningitis Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Vaccine for Non-infectious Meningitis Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Vaccine for Non-infectious Meningitis Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Vaccine for Non-infectious Meningitis Sales by Region (2018-2024) & (K Units)
Table 95. Asia Vaccine for Non-infectious Meningitis Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Country (2024-2029) & (K Units)
Table 109. Serum Institute Company Information
Table 110. Serum Institute Description and Major Businesses
Table 111. Serum Institute Vaccine for Non-infectious Meningitis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 112. Serum Institute Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Serum Institute Recent Developments
Table 114. Sanofi SA Company Information
Table 115. Sanofi SA Description and Major Businesses
Table 116. Sanofi SA Vaccine for Non-infectious Meningitis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 117. Sanofi SA Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Sanofi SA Recent Developments
Table 119. Pfizer Company Information
Table 120. Pfizer Description and Major Businesses
Table 121. Pfizer Vaccine for Non-infectious Meningitis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 122. Pfizer Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Pfizer Recent Developments
Table 124. Nuron Biotech Company Information
Table 125. Nuron Biotech Description and Major Businesses
Table 126. Nuron Biotech Vaccine for Non-infectious Meningitis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 127. Nuron Biotech Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Nuron Biotech Recent Developments
Table 129. JN-International Medical Company Information
Table 130. JN-International Medical Description and Major Businesses
Table 131. JN-International Medical Vaccine for Non-infectious Meningitis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 132. JN-International Medical Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. JN-International Medical Recent Developments
Table 134. Key Raw Materials Lists
Table 135. Raw Materials Key Suppliers Lists
Table 136. Vaccine for Non-infectious Meningitis Distributors List
Table 137. Vaccine for Non-infectious Meningitis Customers List
Table 138. Vaccine for Non-infectious Meningitis Market Trends
Table 139. Vaccine for Non-infectious Meningitis Market Drivers
Table 140. Vaccine for Non-infectious Meningitis Market Challenges
Table 141. Vaccine for Non-infectious Meningitis Market Restraints
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine for Non-infectious Meningitis Product Picture
Figure 2. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Vaccine for Non-infectious Meningitis Market Share by Type in 2022 & 2029
Figure 4. Polysaccharide Vaccines Product Picture
Figure 5. Conjugate Vaccines Product Picture
Figure 6. Combination Vaccines Product Picture
Figure 7. Men B Vaccines Product Picture
Figure 8. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Vaccine for Non-infectious Meningitis Market Share by Application in 2022 & 2029
Figure 10. Meningitis
Figure 11. Septicemia
Figure 12. Others
Figure 13. Vaccine for Non-infectious Meningitis Report Years Considered
Figure 14. Global Vaccine for Non-infectious Meningitis Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Vaccine for Non-infectious Meningitis Revenue 2018-2029 (US$ Million)
Figure 16. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region (2018-2029)
Figure 18. Global Vaccine for Non-infectious Meningitis Sales 2018-2029 ((K Units)
Figure 19. Global Vaccine for Non-infectious Meningitis Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Vaccine for Non-infectious Meningitis Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Vaccine for Non-infectious Meningitis Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Vaccine for Non-infectious Meningitis Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Vaccine for Non-infectious Meningitis Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Vaccine for Non-infectious Meningitis Sales YoY (2018-2029) & (K Units)
Figure 25. China Vaccine for Non-infectious Meningitis Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Vaccine for Non-infectious Meningitis Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Vaccine for Non-infectious Meningitis Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Vaccine for Non-infectious Meningitis Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Vaccine for Non-infectious Meningitis in the World: Market Share by Vaccine for Non-infectious Meningitis Revenue in 2022
Figure 32. Global Vaccine for Non-infectious Meningitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
Figure 34. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
Figure 35. Global Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
Figure 36. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Vaccine for Non-infectious Meningitis Revenue Share by Country (2018-2029)
Figure 42. US & Canada Vaccine for Non-infectious Meningitis Sales Share by Country (2018-2029)
Figure 43. U.S. Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
Figure 46. Europe Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
Figure 47. Europe Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
Figure 48. Europe Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
Figure 49. Europe Vaccine for Non-infectious Meningitis Revenue Share by Country (2018-2029)
Figure 50. Europe Vaccine for Non-infectious Meningitis Sales Share by Country (2018-2029)
Figure 51. Germany Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 52. France Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 56. China Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
Figure 57. China Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
Figure 58. China Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
Figure 59. China Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
Figure 60. Asia Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
Figure 61. Asia Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
Figure 62. Asia Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
Figure 63. Asia Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
Figure 64. Asia Vaccine for Non-infectious Meningitis Revenue Share by Region (2018-2029)
Figure 65. Asia Vaccine for Non-infectious Meningitis Sales Share by Region (2018-2029)
Figure 66. Japan Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 70. India Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Share by Country (2018-2029)
Figure 77. Brazil Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Vaccine for Non-infectious Meningitis Revenue (2018-2029) & (US$ Million)
Figure 82. Vaccine for Non-infectious Meningitis Value Chain
Figure 83. Vaccine for Non-infectious Meningitis Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed